Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with hereditary ATTR amyloidosis with polyneuropathy (a genetic condition that damages nerves), sometimes called hATTR-PN.
- People whose diagnosis has been confirmed by a genetic test showing a change (variant) in the TTR gene.
- People whose nerve damage has been measured using a standard scoring tool (called the Neuropathy Impairment Score) and falls between 5 and 130.
- People whose general physical functioning has been rated at 60% or above on a standard medical scale (called the Karnofsky Performance Status), meaning they are able to care for themselves and carry out normal activity at least some of the time (confirm with trial site).
Who may not be able to join:
- People who have previously had a liver transplant, or who the trial doctor believes are likely to need one during the study.
- People who have a different type of amyloidosis (not the hereditary TTR type), or who show signs of amyloid affecting the membranes around the brain and spinal cord.
- People whose heart failure has been rated above level 2 on the standard New York Heart Association scale, meaning more significant heart-related limitations (confirm with trial site).
- People whose liver enzyme levels (specifically ALT or AST) are more than 2.5 times the upper limit of the normal range on a blood test.
- People whose bilirubin level (a marker of liver function) is more than 1.5 times the upper limit of the normal range on a blood test.
- People whose kidneys are not filtering blood well enough, as measured by a standard kidney function test falling at or below a certain threshold (confirm with trial site for exact values).
- People whose nerve damage is known to be caused by something other than hATTR amyloidosis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Alnylam Pharmaceuticals
Phone: 1-877-ALNYLAM
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.